List view / Grid view
Dr Pushpanathan Muthuirulan explores why messenger RNA (mRNA) is advantageous for vaccine development and how the COVID-19 pandemic has accelerated its progress within the pharmaceutical industry.
![Syringe drawing liquid from a vial labelled 'REMDESIVIR', on a background of abstract SARS-CoV-2 particles [Credit: ffikretow@hotmail.com / Shutterstock.com].](https://www.drugtargetreview.com/wp-content/uploads/remdesivir-SARS-CoV-2-750x500.jpg)
![Syringe drawing liquid from a vial labelled 'REMDESIVIR', on a background of abstract SARS-CoV-2 particles [Credit: ffikretow@hotmail.com / Shutterstock.com].](https://www.drugtargetreview.com/wp-content/uploads/remdesivir-SARS-CoV-2-scaled-e1602154798857.jpg)
Exploring how the Ebola virus develops remdesivir resistance has highlighted a mutation that could allow SARS-CoV-2 to do the same.
A new interactive map of the surface of SARS-CoV-2, featuring the Spike, Envelope and Membrane proteins, has been released for researchers to use.
A compound extracted from the leaf of the American beautyberry re-sensitised methicillin-resistant Staphylococcus aureus (MRSA) to beta-lactam antibiotics.
Researchers isolated monoclonal antibodies from children who has survived infection by EV-D68, the virus linked to acute flaccid myelitis (AFM). These antibodies protected mice against infection.
Dr Mike Tocci discusses how pharmacogenomics can revolutionise medical research and improve the efficacy and quality of drugs.
A new 3D model of the surface of the coronavirus COVID-19 has been released, to aid researchers in the development of a treatment.
